Latest News - Eli Lilly
Top Corporates Hub
Eli Lilly
Our Top 10 High Growth Dividend Stocks - March 2026
21.03.2026 08:15
We use our proprietary models to rate both quantitatively and qualitatively and select the top 10 names from an initial list of nearly 400 dividend stocks. Read the list of March picks here.
Eli Lilly Taps Fauna Bio AI To Expand Long Term Obesity Strategy
21.03.2026 08:04
Fauna Bio and Eli Lilly (NYSE:LLY) identified a new obesity drug target using AI insights from hibernating mammals. The target designation advances their existing discovery partnership focused on metabolic disease. This development adds a non GLP 1 related angle to Eli Lilly's obesity research efforts. Eli Lilly, known for its diabetes and obesity treatments, is already a central player in the fast growing weight management drug space. The new AI derived target with Fauna Bio gives the...
GLP-1 drugs are changing how Americans eat. Food companies are racing to catch up
21.03.2026 08:00
For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses.
Beijing courts Eli Lilly as weight-loss drug race drives $3bn China commitment
21.03.2026 07:45
Investing.com -- Eli Lilly and Company (NYSE:LLY) is deepening its footprint in the world’s second-largest economy, with Chinese Commerce Minister Wang Wentao expressing hope that the pharmaceutical giant will "deepen its commitment" and pursue more aggressive growth targets.
Lilly GLP-1 drug rivals Novo's pipeline treatment on gut side effects but throws up skin concern
20.03.2026 11:12
New trial data complicates the competitive picture in the fast-growing obesity drug market Eli Lilly and Co's (NYSE:LLY) experimental weight-loss and diabetes drug retatrutide has shown a side-effect profile broadly comparable to leading treatments, but new data flagging an unusual skin...
Transformative Or Overhyped? The Impact Of Weight-Loss Drugs On European Food Demand
20.03.2026 05:10
Obesity rates have risen sharply over the past few decades: in 1975, a little over 10% of US adults were obese. Read more here.
RBC Capital Sees Eli Lilly’s (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results
20.03.2026 04:03
Eli Lilly and Company (NYSE:LLY) is included among the 15 Dividend Stocks to Buy for Steady Income. On March 19, RBC Capital said the overall tolerability and A1C reductions for Eli Lilly and Company (NYSE:LLY)’s retatrutide in the TRANSCEND-T2D-1 study came in worse than Mounjaro for type 2 diabetes patients. At the same time, weight loss […]
Is Eli Lilly’s (LLY) Triple Agonist Breakthrough Quietly Redefining Its Obesity Investment Narrative?
20.03.2026 03:11
Eli Lilly recently reported positive topline Phase 3 results from TRANSCEND-T2D-1, showing that its investigational triple agonist retatrutide significantly lowered A1C and reduced body weight over 40 weeks in adults with early type 2 diabetes compared with placebo. By combining GIP, GLP-1 and glucagon receptor activity in a single weekly injection and delivering continued weight loss without a clear plateau at 40 weeks, retatrutide points to a potentially new class of cardiometabolic...
Novo Tries New Japan Strategy To Boost Demand
19.03.2026 19:49
Japan expansion comes as competition heats up
Eli Lilly’s Weight-Loss Drug Candidate Is a Triple Treat. Move Over, Zepbound.
19.03.2026 18:16
Lilly says its experimental drug retatrutide met the primary endpoint and key secondary endpoints in a new study.
AMGN Trading Above 50 & 200-Day SMA: How to Play the Stock?
19.03.2026 16:16
Amgen stock holds above key SMAs as strong drug sales, biosimilars, and MariTide pipeline momentum offset looming patent losses and pricing headwinds.
3 Growth ETFs Down This Month and One of Them Is a Buy
19.03.2026 16:03
FELG and VUG are both down significantly this year, but one of them uses a quantitative model that can shift away from the names dragging it lower. The other cannot. Vanguard Growth Index Fund ETF Shares (NYSEARCA:VUG) has been one of the harder-hit passive growth funds this year, sliding from near $488 at the open ... 3 Growth ETFs Down This Month and One of Them Is a Buy
Eli Lilly’s next-generation obesity drug delivers strong results in late-stage trial
19.03.2026 15:37
Eli Lilly and Co (NYSE:LLY) has reported positive results from its late-stage trial of retatrutide, a next-generation obesity drug, demonstrating significant reductions in blood sugar levels and body weight. The Phase 3 TRANSCEND-T2D-1 trial evaluated retatrutide, a triple hormone receptor...
Top Midday Stories: Qatar Loses 17% of LNG From Iranian Attacks; Micron Shares Fall Despite Strong Q2 Earnings
19.03.2026 15:36
All three major US stock indexes were down in late-morning trading Thursday, as oil prices jumped on
Viking Therapeutics: Phase 3 Obesity Data Feels Like A Coin Toss (Rating Downgrade)
19.03.2026 14:02
Viking Therapeutics, Inc.: VK2735 GLP-1/GIP obesity drug enters Phase 3 with strong cash runway, but rising competition and trial risk. Click for this VKTX update.
Eli Lilly Confirms 'Superior Weight Loss' Of Its Next-Generation Obesity Drug
19.03.2026 13:47
Eli Lilly reported study results Thursday that confirmed the "superior weight loss profile" of its next-gen obesity drug, retatrutide.
FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share
19.03.2026 12:53
The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.
Eli Lilly’s ‘Triple Agonist’ Is More Than Just a Weight-Loss Drug. This Trial Proves It.
19.03.2026 12:50
Lilly says its experimental drug retatrutide met the primary endpoint and key secondary endpoints in a new study.
ABBV Stock Slides 5%: Is J&J's Icotyde a Threat to Skyrizi?
19.03.2026 12:37
AbbVie stock sinks 5% as J&J's newly approved Icotyde raises competitive concerns for blockbuster Skyrizi in the fast-growing IL-23 market.
Lilly’s Retatrutide Shows Significant Improvement In Weight Loss and Blood Sugar
19.03.2026 12:23
Eli Lilly’s experimental weight-loss drug retatrutide met the primary and key secondary endpoints in a trial, showing significant reductions in weight loss and blood sugar levels.